Q1 Earnings Forecast for Biogen Issued By Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Biogen in a report released on Wednesday, February 12th. Leerink Partnrs analyst M. Goodman anticipates that the biotechnology company will earn $3.84 per share for the quarter. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. Leerink Partnrs also issued estimates for Biogen’s Q2 2025 earnings at $4.10 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.85 EPS, FY2026 earnings at $16.45 EPS, FY2027 earnings at $16.40 EPS, FY2028 earnings at $17.65 EPS and FY2029 earnings at $19.50 EPS.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

A number of other analysts have also recently weighed in on BIIB. BMO Capital Markets dropped their price target on Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a research report on Thursday. Wells Fargo & Company cut their target price on Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a research note on Thursday. Piper Sandler lowered shares of Biogen from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $315.00 to $138.00 in a research report on Thursday, January 2nd. Jefferies Financial Group downgraded shares of Biogen from a “buy” rating to a “hold” rating and cut their price objective for the company from $250.00 to $180.00 in a research report on Monday, December 9th. Finally, StockNews.com cut shares of Biogen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 28th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Biogen has an average rating of “Hold” and an average price target of $211.96.

Biogen Price Performance

BIIB opened at $137.33 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The company’s 50-day moving average price is $147.31 and its 200 day moving average price is $173.80. Biogen has a fifty-two week low of $128.51 and a fifty-two week high of $238.00. The firm has a market cap of $20.01 billion, a price-to-earnings ratio of 12.41, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC boosted its stake in shares of Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 141 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen during the fourth quarter valued at $25,000. OFI Invest Asset Management purchased a new stake in shares of Biogen during the fourth quarter valued at $32,000. Ashton Thomas Securities LLC acquired a new position in shares of Biogen in the 3rd quarter valued at $33,000. Finally, SRS Capital Advisors Inc. purchased a new position in Biogen in the 4th quarter worth about $33,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.